Clinical trials: 13-valent Pneumococcal Vaccine
Pneumococcal Disease
Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines
This is an open-label phase III clinical trial. The purpose of this trial is to investigate in detail the kinetics of the immune response to Prevenar-13, a pneumococcal conjugate vaccine, compared to Pneumovax-II, a pneumococcal…
- Trial name
- NCT01432158
- Testing
- Prevenar 13, Pneumovax II
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae.
- Trial name
- NCT00980655
- Testing
- 13vPnC, 23vPS
- Where
- 47 sites in United States, Belgium and 8 more
- Volunteers
- 251 people
- Sponsor
- Pfizer
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
- Trial name
- NCT00743652
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 21 sites in United States
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Vaccines
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC)…
- Trial name
- NCT01392378
- Testing
- 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, Paracetamol
- Where
- 14 sites in Poland
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.
- Trial name
- NCT00676091
- Testing
- 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)
- Where
- 4 sites in Brazil
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccines in…
- Trial name
- NCT00384059
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7vPnC, Pediacel
- Where
- 11 sites in United Kingdom
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pneumococcal Infection
A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
This study is primarily designed to evaluate the IgG immune responses to the 13 pneumococcal serotypes induced by 13vPnC compared with the immune responses induced by 7vPnC when measured 1 month after the infant series, and to…
- Trial name
- NCT01692886
- Testing
- 7-valent Pneumococcal Conjugate Vaccine, 13-valent Pnumococcal Conjugate vaccine
- Where
- 4 sites in China
- Volunteers
- 1,674 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Kidney Failure
13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients
To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are…
- Trial name
- NCT02492438
- Testing
- PPV23 vaccination or PCV13 vaccination
- Where
- 2 sites in Belgium
- Volunteers
- 154 people
- Sponsor
- AZ Sint-Jan AV
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Vaccines
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar.
- Trial name
- NCT00824655
- Testing
- 13vPnC
- Where
- 7 sites in Sweden
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infection, Streptococcus Pneumoniae Infection
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis…
- Conditions
- Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against
- Trial name
- FPCV (NCT03489018)
- Testing
- PCV10, PCV13
- Where
- Kenya
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Pneumococcal Infections
A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
The purpose of this study is to evaluate the safety and immunogenicity of LBVE013 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) or LBVE014 (Pneumococcal 14-valent conjugate vaccine [diphtheria CRM197…
- Trial name
- NCT02892812
- Testing
- Pneumococcal conjugate vaccine
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Meningococcal Disease, Pneumococcal Disease
Hepatitis B Vaccination in Infants
In the UK, infants currently receive a 5-in-1 vaccine (Pediacel) at 2, 3 and 4 months of age, which protects against diphtheria, tetanus, pertussis (whooping cough), polio and Haemophilus influenzae type b (Hib).
- Conditions
- Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease, Diphtheria, Tetanus and Pertussis
- Trial name
- Infanrix (NCT01896596)
- Testing
- Menjugate, Menitorix, NeisVac-C
- Where
- United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Public Health England
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given…
- Trial name
- NCT00366340
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 51 sites in Germany
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Otitis Media
Effect of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01199016
- Testing
- Tympanocentesis, Nose/throat swab, Observational
- Where
- 7 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Pneumococcal Disease
Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers
The purpose of the study is to expand the understanding of the safety profile of 13vPnC in routine use following licensure and introduction of the vaccine.
- Trial name
- NCT01128426
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 53,902 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines
Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
A Phase 4 Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
- Trial name
- NCT03548337
- Testing
- 13vPnC
- Where
- 7 sites in India
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants.
- Trial name
- NCT00444457
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7vPnC
- Where
- 78 sites in United States
- Volunteers
- 1,712 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer